Download VACCINES and VACCINE PROTOCOLS

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
“We must not sacrifice our
future for a momentary
pleasure.”
Canine and Feline
 Vaccines
do not produce immunity in
100% of population
• Should decrease severity
 Protection
of 70% of population sufficient
if communicability is low
 In general practice, 1 vaccine break
constitutes a failure







Illness
Fever
Vaccine reaction from prior vaccine
Medical therapy
Age: In < 5 wks. MLV can cause disease
Pregnancy, whelping, queening
• modified-live virus vaccines can lead to birth
defects or abortions
Problems
• hypertrophic osteodystrophy and juvenile cellulitis - modified-
live virus distemper vaccine in Weimaraners
• vaccine-associated sarcomas in cats : FeLV and Rabies
 MLV
 KILLED
• Strong, long-lasting
•
•
•
•
immune response that
is achieved with fewer
doses
Adjuvants are not as
necessary
Quicker immune
respones
Less chance of allergic
reactions
After it is mixed only
effective 1 hour
(inactivated)
• More stable in storage
• Unlikely to contain
contaminating
pathogens
• Unlikely to cause
disease due to residual
disease-causing
characteristics
• Produce little to no
cellular and mucosal
immunity
NO VACCINE IS 100% EFFECTIVE!
 Chemicals, microbial
components, or
mammalian proteins
 Enhances the immune response to
vaccine antigens
 Aluminum gels/ salts
Severity
of disease
Transmissibility
Zoonotic potential
Recommended by AAHA (American
Animal Health Association)
Those
vaccines that every puppy
should receive; identified by vaccine
experts such as the AAHA Canine
Task Force
• CORE VACCINES FOR CANINES
INCLUDE:
 Canine parvovirus type 2 (CPV-2)
 Canine Distemper virus (CDV)
 rCDV: Recombinat
 Canine
Adenovirus type 2 (CAV-2):
DAPP/DHPP
 CAV-2 protects against both 1 & 2
 CAV-1 causes Infectious Canine Heaptitis
 No CAV-1 vaccine because of anterior uveitis
 Rabies
virus (RV)
• Killed vaccine
• State/provincial/local laws
 Begin: 6-9 weeks of age
• Do not give vaccines earlier than 5-6 weeks
*remember maternal antibody interference
 Frequency: q 2-4 weeks
• May vary according to risk, vaccine
 End: at least one dose should be given
at
age 14-16 weeks of age or older
 Revaccination: at 1 year of age or 1 year
after the last puppy vaccination
•
Rabies vaccine is initially
given at 12 wks of age
– Does not need to be
boostered in 2-4 weeks, but
rather within 12 months.
Each subsequent rabies
vaccine should be given q
3yrs.
– Rabies vaccine is the only
canine vaccine requiring a
minimum duration of
immunity study and
labeled as 1 yr or 3 yr. by
the USDA.

The minimum duration of immunity for the core
vaccines (except rabies) is at least 5-7 yrs. (after initial
puppy set of vxns)
• based on challenge and/or antibody titers
you can even have this done in your own pets to determine his/her
immunity level against a particular disease.

Today, a 3 yr revaccination program has been
recommended in the AAHA Canine Vaccination
Guidelines for dogs and the American Association of
Feline Practitioners Guidelines for cats
 Following
the vaccine label
 Veterinarians resistant to change
 Fear that not revaccinating will cause the
animal to become susceptible soon after
one year.
 Compliance with boarding kennel rules
 Optional
or non-core vaccines should
only be given to animals that need them
and only as often as needed!
• Potential problems: duration of immunity is not
known, the efficacy is limited or not known
 EX: Leptospirosis, Bordetella, Canine
Influenza, Lyme disease, Canine
coronavirus, Giardia (AAHA Guidelines do not
recommend coronavirus or giardia vaccines unless they
can be proven to be beneficial for a certain animal)
•
New vaccines: snakebites (Crotalus sp.
Toxoid, western diamonback rattlesnake),
periodontal disease (porphyromonas sp.),
as well as a therapeutic vaccine for
treatment of canine melanomas.
*VACCINES MUST BE TAILORED
TO THE INDIVIDUAL ANIMAL
-Older/younger animal vs. adult
- bacterial vaccine vs. viral vaccine
– Geographic area
 Begin: 8-10
weeks of age
 Frequency: q 2-4 weeks
 End: last dose at 14-16 weeks of age
 Feline
parvovirus (panleukopenia)
 Feline calicivirus
 Feline herpes virus (viral
rhinotracheitis)
 Rabies virus
• Given at 12-16 weeks of age
 FVRCP
 FeLV
(feline leukemia)
 FIV (feline immunodeficiency virus)
 Chlamydia
 Feline coronavirus (FIP): Reduce cs but
not prevent disease
 Feline Giardia
 Bordetella bronchiseptica
 Feline systemic calicivirus
•
May I use smaller vaccine dose in
small breeds to reduce the risk of
adverse reactions?
– NO- the volume (1.0ml) as recommended by the
manufacturer generally represents the minimum
immunizing dose
• This means that a Great Dane should receive the same
amount of vaccine as a Chihuahua
 May
I vaccinate pregnant pets?
• It is best to avoid this. Risk to the fetuses is a
concern. Assess risk vs. benefit
• Feline parvovirus cerebellar hypoplasia in utero
kitten
 May
I vaccinate a patient while under
anesthesia?
• It is best not to do this. The patient may develop
a hypersensitivity reaction that may be harder to
recognize under anesthesia and may be more
difficult to treat. Risk of vomiting and aspiration
is higher.
 May
I inject a modified live intranasal
Bordetella vaccine?
• NO- the vaccine can cause a severe local
reaction and may even result in death (liver
failure)
• Intranasal vaccines are effective against
respiratory disease, form immunoglobulin A
which produces quick local immunity
 May
I administer a modified live SQ
feline FVRCP oronasally? NO
• Upper respiratory infection can result
• spilled on the cat's fur, and the cat licks up the
spilled vaccine
 Clean off the fur with alcohol
 use dilute bleach for spills in the environment
 contact the manufacturer and begin supportive
treatment, if warranted
 http://veterinaryteam.dvm360.com/firstli
ne/article/articleDetail.jsp?id=672508
 http://www.sheltermedicine.com/?q=no
de/58